Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide ...

risk reduction with use of semaglutide 2.4 mg in a real-world environment1 SCORE is a retrospective, observational analysis of 27,963 patients with obesity or overweight and established ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Not only does it combat diabetes and aid in weight loss, but it also safeguards heart health in all patients at high ...

Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and ...